XSHE
300255
Market cap3.36bUSD
Aug 24, Last price
23.38CNY
1D
-4.69%
1Q
-41.52%
Jan 2017
195.95%
IPO
459.33%
Name
Hebei Changshan Biochemical Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hebei Changshan Biochemical Pharmaceutical Co., Ltd. operates within China, focusing on the entire lifecycle of heparin-based pharmaceuticals – from their initial research and development to manufacturing and sales. Their products are primarily utilized for the treatment of cardiovascular and cerebrovascular diseases. The company offers a broad range of heparin compounds, including crude heparin sodium and refined heparin sodium raw materials. Their portfolio also features a variety of injectable heparin preparations, such as standard heparin sodium injections. Furthermore, they produce both the raw materials and finished injectable forms for several low molecular weight heparins, specifically low molecular weight heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium. Established in the year 2000, Hebei Changshan Biochemical Pharmaceutical Co., Ltd. is headquartered in Shijiazhuang, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||